$1.21
+0.04
(+3.42%)▲
Revenue is up for the last 2 quarters, 24.0K → 317.0K (in $), with an average increase of 92.4% per quarter
Netprofit is down for the last 4 quarters, -23.38M → -44.90M (in $), with an average decrease of 25.7% per quarter
In the last 1 year, Novo Nordisk A/s has given 84.6% return, outperforming this stock by 137.1%
In the last 3 years, Novo Nordisk A/s has given 165.1% return, outperforming this stock by 187.5%
3.31%
Downside
Day's Volatility :7.14%
Upside
3.96%
14.05%
Downside
52 Weeks Volatility :72.56%
Upside
68.07%
Period | Lexicon Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -46.22% | -1.1% | 0.0% |
6 Months | -47.84% | 1.6% | 0.9% |
1 Year | -51.65% | 4.2% | 3.1% |
3 Years | -25.0% | 24.2% | 17.1% |
Market Capitalization | 296.4M |
Book Value | $0.76 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.76 |
PEG Ratio | -0.14 |
Wall Street Target Price | 5.55 |
Profit Margin | 0.0% |
Operating Margin TTM | -31635.14% |
Return On Assets TTM | -37.51% |
Return On Equity TTM | -101.65% |
Revenue TTM | 407.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 805.7% |
Gross Profit TTM | -52.7M |
EBITDA | -128.3M |
Diluted Eps TTM | -0.76 |
Quarterly Earnings Growth YOY | -0.63 |
EPS Estimate Current Year | -0.81 |
EPS Estimate Next Year | -0.76 |
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Next Quarter | -0.17 |
What analysts predicted
Upside of 358.68%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 90.3M | ↑ 8.4% |
Net Income | -129.1M | ↓ 8.75% |
Net Profit Margin | -142.86% | ↑ 26.85% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 63.2M | ↓ 30.03% |
Net Income | -120.5M | ↓ 6.59% |
Net Profit Margin | -190.71% | ↓ 47.85% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 322.1M | ↑ 409.54% |
Net Income | 130.1M | ↓ 207.95% |
Net Profit Margin | 40.4% | ↑ 231.11% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 24.0M | ↓ 92.55% |
Net Income | -58.6M | ↓ 145.01% |
Net Profit Margin | -244.11% | ↓ 284.51% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 298.0K | ↓ 98.76% |
Net Income | -87.8M | ↑ 49.82% |
Net Profit Margin | -29.4K% | ↓ 29204.88% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 139.0K | ↓ 53.36% |
Net Income | -101.9M | ↑ 16.16% |
Net Profit Margin | -73.3K% | ↓ 43892.02% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 37.0K | ↑ 164.29% |
Net Income | -23.5M | ↓ 8.34% |
Net Profit Margin | -63.4K% | ↑ 119487.06% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 35.0K | ↓ 5.41% |
Net Income | -24.6M | ↑ 4.73% |
Net Profit Margin | -70.2K% | ↓ 6799.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 39.0K | ↑ 11.43% |
Net Income | -23.4M | ↓ 4.88% |
Net Profit Margin | -60.0K% | ↑ 10281.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 67.0K | ↑ 71.79% |
Net Income | -30.5M | ↑ 30.39% |
Net Profit Margin | -45.5K% | ↑ 14453.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.0K | ↓ 64.18% |
Net Income | -30.9M | ↑ 1.35% |
Net Profit Margin | -128.8K% | ↓ 83257.4% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 317.0K | ↑ 1220.83% |
Net Income | -44.9M | ↑ 45.3% |
Net Profit Margin | -14.2K% | ↑ 114605.53% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 436.5M | ↓ 8.22% |
Total Liabilities | 384.4M | ↑ 20.81% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 284.1M | ↓ 34.91% |
Total Liabilities | 310.5M | ↓ 19.22% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 417.7M | ↑ 47.01% |
Total Liabilities | 300.6M | ↓ 3.2% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 203.8M | ↓ 51.21% |
Total Liabilities | 47.4M | ↓ 84.23% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 136.9M | ↓ 32.82% |
Total Liabilities | 23.3M | ↓ 50.83% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 194.3M | ↑ 41.92% |
Total Liabilities | 77.2M | ↑ 231.02% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 136.2M | ↓ 0.53% |
Total Liabilities | 43.5M | ↑ 86.5% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 112.3M | ↓ 17.52% |
Total Liabilities | 41.5M | ↓ 4.57% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 191.7M | ↑ 70.65% |
Total Liabilities | 47.7M | ↑ 14.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 194.3M | ↑ 1.36% |
Total Liabilities | 77.2M | ↑ 61.9% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 162.7M | ↓ 16.25% |
Total Liabilities | 74.7M | ↓ 3.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 316.7M | ↑ 94.65% |
Total Liabilities | 130.4M | ↑ 74.59% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -185.4M | ↑ 5.56% |
Investing Cash Flow | 50.5M | ↑ 176.8% |
Financing Cash Flow | 149.9M | ↑ 15090.78% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -148.6M | ↓ 19.84% |
Investing Cash Flow | 169.6M | ↑ 235.65% |
Financing Cash Flow | -2.2M | ↓ 101.5% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 113.8M | ↓ 176.58% |
Investing Cash Flow | -155.9M | ↓ 191.91% |
Financing Cash Flow | -2.2M | ↓ 0.8% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -143.0M | ↓ 225.62% |
Investing Cash Flow | 380.8M | ↓ 344.3% |
Financing Cash Flow | -147.6M | ↑ 6532.35% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -87.0M | ↓ 39.14% |
Investing Cash Flow | 2.1M | ↓ 99.45% |
Financing Cash Flow | 22.7M | ↓ 115.38% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -88.9M | ↑ 2.11% |
Investing Cash Flow | -71.1M | ↓ 3468.63% |
Financing Cash Flow | 142.2M | ↑ 526.22% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -23.4M | ↑ 2.6% |
Investing Cash Flow | -4.4M | ↓ 172.31% |
Financing Cash Flow | 23.3M | ↓ 305.67% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.4M | ↑ 4.27% |
Investing Cash Flow | -13.6M | ↑ 209.62% |
Financing Cash Flow | 94.0M | ↑ 303.79% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.4M | ↓ 20.4% |
Investing Cash Flow | -77.2M | ↑ 465.62% |
Financing Cash Flow | 94.0M | ↑ 0.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.6M | ↑ 10.96% |
Investing Cash Flow | 24.2M | ↓ 131.32% |
Financing Cash Flow | 24.9M | ↓ 73.51% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -38.1M | ↑ 20.57% |
Investing Cash Flow | -74.6M | - |
Financing Cash Flow | 189.0M | ↓ 23036.29% |
Sell
Neutral
Buy
Lexicon Pharmaceuticals, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Lexicon Pharmaceuticals, Inc. | -34.59% | -47.84% | -51.65% | -25.0% | -89.17% |
![]() Moderna, Inc. | -13.8% | -33.86% | -19.73% | 39.08% | 427.53% |
![]() Regeneron Pharmaceuticals, Inc. | 0.18% | 1.46% | 18.0% | 45.55% | 106.02% |
![]() Novo Nordisk A/s | -2.09% | 18.19% | 91.43% | 165.4% | 285.43% |
![]() Seagen, Inc. | 4.8% | 8.3% | 56.96% | 13.46% | 180.29% |
![]() Vertex Pharmaceuticals Incorporated | 0.03% | 14.01% | 23.51% | 31.36% | 85.35% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Lexicon Pharmaceuticals, Inc. | NA | NA | -0.14 | -0.81 | -1.02 | -0.38 | 0.0 | 0.76 |
![]() Moderna, Inc. | 35.31 | 35.31 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.73 | 21.73 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 42.99 | 42.99 | 2.03 | 1.65 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 27.12 | 27.12 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Lexicon Pharmaceuticals, Inc. | Buy | $286.6M | -89.17% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $37.4B | 427.53% | 35.31 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.4B | 106.02% | 21.73 | 33.93% |
![]() Novo Nordisk A/s | Buy | $407.6B | 285.43% | 42.99 | 33.4% |
![]() Seagen, Inc. | Hold | $40.6B | 180.29% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.8B | 85.35% | 27.12 | 35.4% |
Artal Group S A
Bvf Inc
FMR Inc
Vanguard Group Inc
BlackRock Inc
JPMorgan Chase & Co
Lexicon Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read Morecorporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Organization | Lexicon Pharmaceuticals, Inc. |
Employees | 135 |
CEO | Mr. Lonnel Coats |
Industry | Health Technology |